InsiderTradesSIGMA

PicksTOP Companies Executives Performance Blog Topics

InsidersTradesSigma

InsiderTradesSIGMA

Multi-market insider intelligence. Official public filings, re-aggregated and scored. Private beta.

FRUSDEGBCHCAITESNLBENOSEFIDKAUATIEBRINJP+ 8 markets

Recommendations
Companies
Insiders
Performance
Backtest
Compare

Methodology
How it works
Glossary
API docs
Status
Blog

Sign in
Create account
Portfolio
API keys
Alerts
Upgrade

Privacy
Terms
Cookies
Contact
About

Built in Paris. Public sources across 28 markets: AMF France, SEC EDGAR Form 4 US, BaFin Germany, SIX SER Switzerland, RNS United Kingdom, SEDI Canada, Consob Italy, CNMV Spain, AFM Netherlands, FSMA Belgium, Oslo Bors Norway, Nasdaq Helsinki, Nasdaq Copenhagen, ASX Australia, FMA Austria, CVM Brazil, HKEX Hong Kong, BSE-Sofia Bulgaria, Tadawul Saudi Arabia, DART South Korea, EDINET Japan, SSE and SZSE China, SEBI India, KNF Poland, PSE Philippines, NZX New Zealand, JSE South Africa. Prices + fundamentals via Yahoo Finance, STOXX 600 sector ETFs (iShares Xetra). Stack: Next.js 16, Prisma, Vercel. Live out-of-sample tracker since 2026-05-16. Methodology audits: /methodologie and /docs/method-review/.

Sources: official public filings under MAR Art.19 (EU and EEA), SEC Section 16 / Form 4 (US), Art.56 SESTA (CH, SIX SER), NI 55-104 / SEDI (CA), Corporations Act s205G (AU) and equivalent regimes. Signals on this site are for educational use only and do not constitute investment advice within the meaning of MiFID II / SEC Reg-IA. Past performance does not guarantee future results. Swiss SIX SER filings are anonymised by law (role only, no name).

Theme: dark (range regime detected on CAC40 90d · as of 2026-05-25)

© 2026 Insiders TradesΣ·Private beta·Hosted on Vercel

All systems operational

InsidersTradesSigma

Lytix Biopharma AS — personal trades · 3 disclosures

← Executives ★ Sign in to follow

LB

Lytix Biopharma AS

NONO·Oslo Børs

Lytix Biopharma ASA

0

Total declarations

0

Company

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Discover the full record of transactions filed by Lytix Biopharma AS. Insider active across 1 companies, notably Lytix Biopharma ASA. Cumulatively, 3 reports have been logged. The latest transaction was disclosed on 26 August 2022 — Purchase. Regulator: Oslo Børs. The full history is accessible without signup.

Declarations3 total

Executives◇OptionsLLytix Biopharma ASA0Oslo

L

Lytix Biopharma AS

OptionMERK

OSLO:654449·1 Sept 2025

Executives◇OptionsLLytix Biopharma ASA0Oslo

L

Lytix Biopharma AS

OptionMERK

OSLO:587883·18 Apr 2023

Executives●PurchaseLLytix Biopharma ASA0Oslo

L

Lytix Biopharma AS

€10,41513,000 shares@ €0.8011

ShareMERK

OSLO:569869·26 Aug 2022

Ideal exit: 23 May 2023 (T+270)

3 of 3 declarations